Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.47 +1.59%

+$0.19 today

Market cap
$606.42M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.32M

Average 0.74M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$54.36M

FY 2025 · Annual

Investing Cash Flow

$22.91M

FY 2025 · Annual

-47.9% YoY

Financing Cash Flow

$25.74M

FY 2025 · Annual

+4917.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Depreciation & Amortization129K406K537K596K(2.63M)
Deferred Income Tax00000
Stock-Based Compensation4.69M10.93M13.09M13.07M14.55M
Change in Working Capital1.4M1.99M728K(993K)3.11M
Accounts Receivables00000
Inventory00000
Accounts Payables2.41M5.39M(1.25M)(1.22M)4.49M
Other Working Capital(1.02M)(3.39M)1.97M226K(1.38M)
Other Non-Cash Items(58K)(1.33M)(6.05M)(6.19M)406K
Operating Cash Flow(29.38M)(51.32M)(58.56M)(43.11M)(54.36M)
Capital Expenditures(1.54M)(918K)(256K)(340K)(193K)
Acquisitions (Net)52.11K39K000
Purchases of Investments(86.26M)(313M)(224.7M)(230.18M)(291.78M)
Sales of Investments34.16M92.89M277.5M274.47M314.89M
Other Investing Activities(52.11K)0000
Investing Cash Flow(53.64M)(220.99M)52.54M43.96M22.91M
Debt Repayment00000
Common Stock Issued254.27M662K724K513K25.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities228K(427K)000
Financing Cash Flow379.21M235K724K513K25.74M
Effect of Forex Changes00000
Net Change in Cash296.19M(272.07M)(5.3M)1.36M(5.71M)
Free Cash Flow(30.92M)(52.24M)(58.82M)(43.45M)(54.55M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$69.8M
+ D&A-$2.6M
+ Stock-Based Comp$14.5M
+ Deferred Tax$0
+ Working Capital$3.1M
+ Other Non-Cash$406.0K
= Operating Cash Flow-$54.4M
- Capex-$193.0K
= Free Cash Flow-$54.6M

Analysis

FY2025 free cash flow is -$54.6M. FCF conversion is 78.2% of net income. Operating cash flow was -$54.4M, with capex of -$193.0K. The largest bridge item is Stock-Based Comp at $14.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
EFFECTEFFECT filingNov 12, 2026
424B5424B5 filingNov 4, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 4, 2026
S-3S-3 filingNov 4, 2026

Does DSGN generate free cash flow?

Design Therapeutics, Inc. (DSGN) generated -$54.55M of free cash flow in fiscal 2025.

How much operating cash flow does DSGN produce?

Operating cash flow was -$54.36M, before capital expenditures of $193,000.00.